Overview
Overview
Testagen is a synthetic tetrapeptide with the sequence Lys‑Glu‑Asp‑Gly (KEDG), an anterior pituitary‑derived bioregulator studied for its role in modulating endocrine function, particularly the pituitary–gonadal axis[1][2]. Preclinical research indicates effects on thyroid hormone normalization and male reproductive hormone modulation[3][4]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements. Reconstitute: Add
- Category
- Longevity
- Routes
- subcutaneous
Mechanism
Testagen
Mechanism of action
Mechanism of action
Testagen (Lys‑Glu‑Asp‑Gly) belongs to a class of short bioregulatory peptides derived from anterior pituitary extracts [1] . Preclinical research in avian models demonstrates that this tetrapeptide can normalize thyroid hormone levels in hypophysectomized subjects and modulate endocrine signaling along the pituitary–gonadal axis [3] [4] . These peptides are hypothesized to act through gene‑regulatory mechanisms influencing hormone synthesis and secretion [2] . No human clinical trials exist; current understanding is extrapolated from preclinical and in vitro studies.
Key research findings
- 01
In a HeLa cell study, fluorescein-labeled Testagen (Lys-Glu-Asp-Gly) entered the cytoplasm, nucleus, and nucleolus and showed sequence-specific binding to deoxyribooligonucleotides and DNA, with apparent preference for CAG-containing sequences, suggesting a proposed epigenetic-style interaction with nucleic acids (PubMed PMID 22117547; DOI 10.1134/S0006297911110022).
- 02
Testagen (KEDG) was among short peptides shown to bind FITC-labeled wheat histones (H1, H2B, H3, H4) in a site-specific manner, supporting a proposed chromatin/gene-activity modulation mechanism for this peptide class (PubMed PMID 23581987; DOI 10.1134/S0006297913020053).
- 03
In neonatally hypophysectomized chickens, administration of Testagen (Lys-Glu-Asp-Gly, derived from anterior-pituitary peptide composition) was associated with higher thyrotropic and thyroid hormone concentrations and with recovery of thyroid gland structure in the hypophysectomy model (PubMed PMID 19024016; DOI 10.1007/s10517-008-0033-6; corroborated in PMID 22268052, DOI 10.1007/s10517-011-1177-3, and Russian-language PMID 21809626).
- 04
In hypophysectomized young and old birds, Testagen promoted recovery of thymus morphological structure, reported as more pronounced for thymic structure than the related peptide Ala-Glu-Asp-Gly (PubMed PMID 23658898; DOI 10.1007/s10517-013-2029-0).
- 05
Molecular-docking work modeled Testagen (KEDG) as an efficient ligand of the LAT1/LAT2 amino-acid and PEPT1 peptide transporters, offering a hypothesized route for cellular uptake of ultrashort peptides (PubMed PMID 36979488; DOI 10.3390/biom13030552).
- 06
A peer-reviewed review of short-peptide regulation of cell differentiation lists KEDG among peptides reported to stimulate immune-cell differentiation, situating Testagen within the broader Khavinson ultrashort-peptide framework rather than as an independently validated agent (PubMed PMID 31808038; DOI 10.1007/s12015-019-09938-8).
Primary source: According to PubMed, the verifiable research base for Testagen (KEDG / Lys-Glu-Asp-Gly) is limited peer-reviewed data and early-stage: a small number of in vitro molecular-interaction studies (DNA/histone binding, transporter docking) and animal experiments in hypophysectomized birds, largely from a few affiliated Russian research groups, with no human studies located. Notably, despite "testosterone/testis" commercial positioning, the indexed biological literature concerns pituitary-derived regulation of the thyroid and thymus and in vitro nucleic-acid/histone binding rather than gonadal or testosterone endpoints, so the compound should be treated as a sparsely characterized research peptide.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Preclinical studies suggest normalization of thyroid hormone parameters in hypophysectomized models[3][4].
Research indicates potential modulation of male reproductive hormones via pituitary pathways[2].
No published human safety or efficacy data; side‑effect profile in humans remains unknown.
Occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.
Protocol Reference
Protocol reference
Commonly cited research range: 100–300 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
100 mcg (0.1 mg)
Weeks 3–4
150 mcg (0.15 mg)
Weeks 5–8
200 mcg (0.2 mg)
Weeks 9–12 (optional)
250–300 mcg (0.25–0.3 mg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.1 mg) | 1.5 units (0.015 mL) |
| Weeks 3–4 | 150 mcg (0.15 mg) | 2.25 units (0.0225 mL) |
| Weeks 5–8 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 9–12 (optional) | 250–300 mcg (0.25–0.3 mg) | 3.75–4.5 units (0.0375–0.045 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake)[5].
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Preclinical bioregulator research reports endocrine-modulating activity; human data are absent.
According to PubMed, the verifiable research base for Testagen (KEDG / Lys-Glu-Asp-Gly) is limited peer-reviewed data and early-stage: a small number of in vitro molecular-interaction studies (DNA/histone binding, transporter docking) and animal experiments in hypophysectomized birds, largely from a few affiliated Russian research groups, with no human studies located. Notably, despite "testosterone/testis" commercial positioning, the indexed biological literature concerns pituitary-derived regulation of the thyroid and thymus and in vitro nucleic-acid/histone binding rather than gonadal or testosterone endpoints, so the compound should be treated as a sparsely characterized research peptide.
- 01In a HeLa cell study, fluorescein-labeled Testagen (Lys-Glu-Asp-Gly) entered the cytoplasm, nucleus, and nucleolus and showed sequence-specific binding to deoxyribooligonucleotides and DNA, with apparent preference for CAG-containing sequences, suggesting a proposed epigenetic-style interaction with nucleic acids (PubMed PMID 22117547; DOI 10.1134/S0006297911110022).
- 02Testagen (KEDG) was among short peptides shown to bind FITC-labeled wheat histones (H1, H2B, H3, H4) in a site-specific manner, supporting a proposed chromatin/gene-activity modulation mechanism for this peptide class (PubMed PMID 23581987; DOI 10.1134/S0006297913020053).
- 03In neonatally hypophysectomized chickens, administration of Testagen (Lys-Glu-Asp-Gly, derived from anterior-pituitary peptide composition) was associated with higher thyrotropic and thyroid hormone concentrations and with recovery of thyroid gland structure in the hypophysectomy model (PubMed PMID 19024016; DOI 10.1007/s10517-008-0033-6; corroborated in PMID 22268052, DOI 10.1007/s10517-011-1177-3, and Russian-language PMID 21809626).
- 04In hypophysectomized young and old birds, Testagen promoted recovery of thymus morphological structure, reported as more pronounced for thymic structure than the related peptide Ala-Glu-Asp-Gly (PubMed PMID 23658898; DOI 10.1007/s10517-013-2029-0).
- 05Molecular-docking work modeled Testagen (KEDG) as an efficient ligand of the LAT1/LAT2 amino-acid and PEPT1 peptide transporters, offering a hypothesized route for cellular uptake of ultrashort peptides (PubMed PMID 36979488; DOI 10.3390/biom13030552).
- 06A peer-reviewed review of short-peptide regulation of cell differentiation lists KEDG among peptides reported to stimulate immune-cell differentiation, situating Testagen within the broader Khavinson ultrashort-peptide framework rather than as an independently validated agent (PubMed PMID 31808038; DOI 10.1007/s12015-019-09938-8).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Testagen.
- 01MDPI Molecules — The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces (structural characterization) View Source
- 02MDPI Molecules — Peptide Regulation of Gene Expression: A Systematic Review (bioregulatory peptide mechanisms) View Source
- 03PubMed — Effects of hypophyseal Lys‑Glu‑Asp‑Gly peptide on immunity, hemostasis, and thyroid function in hypophysectomized chickens View Source
- 04PubMed — Effects of Lys‑Glu‑Asp‑Gly peptide on hormonal activity and thyroid morphology in hypophysectomized mature and old birds View Source
- 05GenScript — Peptide Storage and Handling Guidelines (reconstitution and stability best practices) View Source
- 06JPT Peptide Technologies — How Long Do Peptides Last? (stability and storage considerations) View Source
- 07CDC — Vaccine Administration: Subcutaneous Injection Technique (angle, site, no aspiration) View Source
- 08MedlinePlus — Subcutaneous (SQ) Injections: Patient Instructions (site rotation and technique) View Source
- 09PMC — Subcutaneous Drug Delivery: Pharmacologic Considerations and Clinical Practice View Source
- 10PMC — Subcutaneous Injection Route: Pharmacokinetics and Clinical Applications Review View Source
- 11NCBI Bookshelf — Best Practices for Injection (asepsis, preparation, and administration) View Source
- 12Pure Lab Peptides — Testagen (20 mg) product page (quality and batch documentation) View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Current evidence is limited to in vitro and/or animal-model research; human data are minimal or absent. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Testagenthis | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly) studied for modulation of endocrine function, particularly pituitary-gonadal regulatory pathways. | subcutaneous | Investigational / RUO |
| Vesugen (Lys-Glu-Asp) | A synthetic tripeptide bioregulator (Lys-Glu-Asp) studied for gene-regulatory support of vascular endothelial tissue. | subcutaneous | Investigational / RUO |
| Vilon | A synthetic immunoregulatory dipeptide (Lys-Glu) studied for gene-regulatory and immunomodulatory activity, including effects on lymphocyte markers and chromatin structure. | subcutaneous | Investigational / RUO |
| Cartalax | A synthetic tripeptide bioregulator (Ala-Glu-Asp) studied for gene-regulatory activity in connective and cartilage tissue, with proposed anti-inflammatory and regenerative effects. | subcutaneous | Investigational / RUO |
| Chonluten | A short tripeptide bioregulator (Glu-Asp-Gly) studied for effects on bronchopulmonary tissue and modulation of inflammatory signaling in monocyte/macrophage models. | subcutaneous | Investigational / RUO |
| Thymosin Alpha-1 | A 28-amino-acid thymic peptide that modulates immune function, studied for enhancement of T-cell maturation, dendritic-cell function, and Toll-like-receptor signaling. | subcutaneous | Investigational / RUO |
| Tirzepatide | Activates both GIP and GLP-1 receptors, providing synergistic effects on insulin secretion, glucose control, and appetite regulation. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Testagen is a synthetic ultrashort tetrapeptide with the sequence Lys-Glu-Asp-Gly (KEDG), part of the Khavinson family of peptide bioregulators developed for laboratory research. Its identity and four-residue sequence are confirmed in indexed literature (PubMed PMID 22117547; PMID 40807317, DOI 10.3390/molecules30153141).
The verifiable indexed studies fall into two groups: in vitro binding of KEDG to DNA/oligonucleotides and to histones (PMID 22117547; PMID 23581987), and animal experiments in hypophysectomized birds examining thyroid and thymus structure and hormone markers (PMID 19024016; PMID 23658898). No human studies were located.
Based on the literature located, no. The indexed peer-reviewed record does not contain testis- or testosterone-specific studies of KEDG; that positioning appears in commercial material rather than in indexed research. This is a clear evidence gap and should be interpreted cautiously. This is research information, not medical advice.
It is limited peer-reviewed data and preliminary in nature: a handful of in vitro, computational, and animal-model reports concentrated among a few affiliated research groups, with no replicated human data. Findings are best regarded as hypothesis-generating for research rather than as established effects.
Proposed mechanisms are epigenetic-style: cell- and nucleus-penetration with sequence-specific binding to DNA and histones, hypothesized to influence gene-activity regulation (PMID 22117547; PMID 23581987; review PMID 31808038). Computational work additionally models cellular uptake via LAT/PEPT transporters (PMID 36979488). These mechanisms are proposed and not confirmed in vivo in humans.
No validated human dosing protocols exist in the peer-reviewed literature. Research-reported amounts vary by experimental model and are not transferable to humans; for any protocol question, consult the designated protocol reference. This is not medical advice.
Reported observations are limited to the experimental endpoints above, such as changes in thyroid and thymus structure and hormone markers in birds and in vitro binding behavior. No human observed-effects-in-research data were located, so research-grade conclusions about observed effects in people cannot be drawn.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.